Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study for Patients With Advanced Triple Negative or Metaplastic HR-positive/HER2-negative, PIK3CA/PTEN-altered Breast Cancer Treated With Eribulin in Combination With MEN1611

NCT05810870 is registered in ClinicalTrials.gov with MedSIR as lead sponsor.

NCT NCT05810870
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05810870 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study for Patients With Advanced Triple Negative or Metaplastic HR-positive/HER2-negative, PIK3CA/PTEN-altered Breast Cancer Treated With Eribulin in Combination With MEN1611
Lead sponsor
MedSIR
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 24, 2023
Completion date
July 31, 2027
Enrollment
14 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, breast cancer, metastatic breast cancer